Hydrochloric Acid

Hydrochloric Acid

SCHEMBL2581982

NCc1ccc(F)c(Cl)c1Cl.[Cl-].[H+]

nearest known ligand 0.45

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PNMT P11086 2/20 0.45
LOXL2 Q9Y4K0 1/20 0.41
PDCD1LG2 Q9BQ51 2/20 0.39
CD274 Q9NZQ7 2/20 0.39
TAAR1 Q96RJ0 5/20 0.36
DPP4 P27487 2/20 0.36
P2RX7 Q99572 3/20 0.33
HTR2A P28223 2/20 0.32
HTR2C P28335 2/20 0.32
HTR2B P41595 2/20 0.32
CYP2A6 P11509 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
TNF P01375 1/20 0.31
RIPK1 Q13546 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31287302 0.96 PNMT (0.48) PNMTLOXL2PDCD1LG2CD274TAAR1
SCHEMBL22469536 0.96 PNMT (0.48) PNMTLOXL2PDCD1LG2CD274TAAR1
Hydrochloric Acid SCHEMBL2577836 0.93 PNMT (0.46) PNMTLOXL2PDCD1LG2CD274TAAR1
SCHEMBL1635301 0.80 PNMT (0.46) PNMTLOXL2PDCD1LG2CD274TAAR1
SCHEMBL29799944 0.80 PNMT (0.46) PNMTLOXL2PDCD1LG2CD274TAAR1
SCHEMBL1765164 0.80 PNMT (0.46) PNMTLOXL2PDCD1LG2CD274TAAR1
Hydrochloric Acid SCHEMBL18109266 0.78 PNMT (0.45) PNMTLOXL2PDCD1LG2CD274TAAR1
Hydrochloric Acid SCHEMBL1637469 0.78 PNMT (0.45) PNMTLOXL2PDCD1LG2CD274TAAR1
SCHEMBL27846447 0.78 PNMT (0.45) PNMTLOXL2PDCD1LG2CD274TAAR1
SCHEMBL210553 0.77 PNMT (0.60) PNMTLOXL2TAAR1DPP4MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2049478-B1 SUBSTITUTED N-PHENYLMETHYL -5-OXO-PROLINE-2-AMIDES AS P2X7-RECEPTOR ANTAGONISTS AND THEIR METHODS OF USE GLAXO GROUP LTD (GB) 2012-05-30 EP disclosed
US-8048907-B2 Receptor antagonists and their methods of use GLAXO GROUP LIMITED (GB) 2011-11-01 US disclosed
US-20100144829-A1 Novel Receptor Antagonists and Their Methods of Use GLAXO GROUP LIMITED 2010-06-10 US disclosed
US-7718693-B2 Receptor antagonists and their methods of use GLAXO GROUP LIMITED (GB) 2010-05-18 US disclosed
WO-2009074518-A1 COMBINATIONS OF PROLINAMIDE P2X7 MODULATORS WITH FURTHER THERAPEUTIC AGENTS GLAXO GROUP LIMITED (GB) 2009-06-18 WO disclosed
US-20080009541-A1 Novel Receptor Antagonists and Their Methods of Use GLAXO GROUP LIMITED (GB) 2008-01-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080009541-A1 Novel Receptor Antagonists and Their Methods of Use P2RX7, P2RX3, P2RX1 PNMT 2278/4885LOXL2 1830/4885PDCD1LG2 2556/4885
US-20100144829-A1 Novel Receptor Antagonists and Their Methods of Use P2RX7, P2RX3, P2RX1 PNMT 2278/4885LOXL2 1830/4885PDCD1LG2 2556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.